



April 24, 2023

Company Name: AnGes Inc.

Representative: Ei Yamada, President & CEO

## Notice Concerning Acquisition and Cancellation of the 42nd Series of Stock Acquisition Rights

AnGes announces that on April 24, 2023, AnGes's Representative Director decided to acquire the 42nd Series of Stock Acquisition Rights issued on October 12, 2022, after suspending the exercise of all remaining Stock Acquisition Rights, and that at the Board of Directors meeting held on the same day, we resolved to cancel all acquired Stock Acquisition Rights immediately after acquisition, as described below.

### 1. Details of the Stock Acquisition Rights to be acquired and cancelled

(1) Name of the Stock Acquisition Rights	AnGes Inc. The 42nd series of stock acquisition rights
(2) Number of Stock Acquisition Rights Issued	380,000 units
(3) Number of Stock Acquisition Rights to be acquired and cancelled	38,500 units
(4) Acquisition price of the Stock Acquisition Rights and the total amount thereof	134 yen per stock acquisition right Total amount 5,159,000 yen
(5) Date of acquisition and retirement of the Stock Acquisition Rights	May 9, 2023
(6) Number of Stock Acquisition Rights remaining after cancelled	0 unit

### 2. Reason for Acquisition and Cancellation of Stock Acquisition Rights

On October 12, 2022, AnGes issued these equity warrants to fund the operations of EmendoBio Inc., a subsidiary engaged in research and development of genome editing technology, and to strengthen AnGes's business foundation.

The minimum exercise price of the Stock Acquisition Rights was set at 124 yen, and AnGes's stock price after the issuance of the Stock Acquisition Rights remained above such minimum exercise price, resulting in the Stock Acquisition Rights being exercised and the fundraising being able to proceed. However, the exercise of the remaining number (38,500 units) of these stock acquisition rights has not progressed, as AnGes's stock price is currently below the minimum exercise price of these rights.

We have decided to acquire and cancel the remaining Stock Acquisition Rights as a result of a comprehensive review of the share price trend since the issuance of the Stock Acquisition Rights, the future capital policy of AnGes, and the future market environment.

(Note) This document has been translated from the Japanese original for reference purposes only.  
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



### 3. Future outlook

The use of funds from the acquisition and retirement of these stock acquisition rights has not been determined at this time, and will be announced once it is determined.

The acquisition and cancellation of the Stock Acquisition Rights will not have a material impact on our consolidated financial results for the fiscal year ending December 31, 2023. If any matters arise that should be disclosed in the future, we will promptly notify you.

(Note) This document has been translated from the Japanese original for reference purposes only.  
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.